PolyPid Ltd. (PYPD)
NASDAQ: PYPD · Real-Time Price · USD
4.170
-0.180 (-4.14%)
At close: Mar 12, 2026, 4:00 PM EDT
4.190
+0.020 (0.48%)
After-hours: Mar 12, 2026, 4:10 PM EDT
PolyPid Employees
As of December 31, 2025, PolyPid had 73 total employees, including 69 full-time and 4 part-time employees. The number of employees increased by 13 or 21.67% compared to the previous year.
Employees
73
Change (1Y)
13
Growth (1Y)
21.67%
Revenue / Employee
n/a
Profits / Employee
-$468,068
Market Cap
79.58M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 73 | 13 | 21.67% | 69 | 4 |
| Dec 31, 2024 | 60 | -2 | -3.23% | 57 | 3 |
| Dec 31, 2023 | 62 | 2 | 3.33% | 59 | 3 |
| Dec 31, 2022 | 60 | -19 | -24.05% | 57 | 3 |
| Dec 31, 2021 | 79 | 10 | 14.49% | 75 | 4 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Champions Oncology | 213 |
| Pliant Therapeutics | 171 |
| Seres Therapeutics | 103 |
| PMV Pharmaceuticals | 47 |
| Q32 Bio | 26 |
| iBio, Inc. | 20 |
| Cingulate | 13 |
| MAIA Biotechnology | 13 |
PYPD News
- 15 days ago - PolyPid Announces Participation in Upcoming Investor Conferences - GlobeNewsWire
- 4 weeks ago - PolyPid Ltd. (PYPD) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - PolyPid Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results - GlobeNewsWire
- 6 weeks ago - PolyPid to Report Fourth Quarter 2025 Financial Results and Operational Highlights on February 11, 2026 - GlobeNewsWire
- 3 months ago - PolyPid Appoints Veteran MedTech Leader Brooke Story as Chairman of the Board of Directors - GlobeNewsWire
- 3 months ago - PolyPid Ltd. (PYPD) Discusses the Science and Business Case for D-PLEX100 in Tackling Surgical Site Infections Transcript - Seeking Alpha
- 3 months ago - PolyPid Announces Positive FDA Pre-NDA Meeting Minutes for D-PLEX₁₀₀ Supporting NDA Submission - GlobeNewsWire
- 3 months ago - PolyPid to Participate in ROTH Capital Partners Virtual KOL Event on December 10, 2025 - GlobeNewsWire